Structure-function relationship of estrogen receptors in cardiovascular pathophysiological models

被引:10
作者
Arnal, Jean-Francois [1 ]
Valera, Marie-Cecile
Payrastre, Bernard
Lenfant, Francoise
Gourdy, Pierre
机构
[1] Univ Toulouse, Fac Med, INSERM, U1048,I2MC, F-31432 Toulouse, France
关键词
VASCULAR INJURY RESPONSE; HORMONE-THERAPY; POSTMENOPAUSAL WOMEN; ACTIVATION-FUNCTION; PROMOTER-CONTEXT; ER-ALPHA; BETA; ESTRADIOL; DISEASE; RISK;
D O I
10.1016/j.thromres.2012.08.261
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The ancestral status of estrogen receptor (ER) in the family of the steroid receptors has probably contributed to the pleiotropic actions of estrogens, and in particular of 17 beta-estradiol (E2). Indeed, in addition to their well described role in sexual development and reproduction, they influence most of the physiological processes. The pathophysiological counterpart of these actions includes several highly beneficial effects such as prevention of osteoporosis, atheroma and type 2 diabetes,. However, estrogens also promotes two deleterious actions : the stimulation of the proliferation of the epithelium of two sex targets : uterus and breast, favoring an increase in risk of epithelial cancer in these two tissues. These actions are mediated by the activation of ER alpha (ERa) and beta (ER beta), which regulate target gene transcription (genomic action) through two independent activation functions AF-1 and AF-2, but can also elicit rapid membrane initiated steroid signals. Although ER beta plays an important role in the central nervous system and in the heart, ERa appears to play a prominent role in most of the other tissues. One major challenge consists in uncoupling some beneficial actions from other deleterious ones, i. e. selective ER modulation. Tamoxifen and raloxifen are beneficial to prevent the recurrence of breast cancer, and mimic estrogen action mainly on bone, but their effets on atheroma and on type 2 diabetes are if any marginal. These last years, several labs, and in particular our lab, have attempted: 1) To perform an in vivo molecular "dissection" of ERa, allowing the uncoupling of some of its actions, and potentially paving the way to optimized selective ER modulators. (reviewed in Arnal JF, et al. Br J Pharmacol. 2012; 165: 57-66). 2) To describe an unexpected action of E2 treatment at the level of platelet responses in mice, that protects the animals from thromboembolism through the haematopoietic ERa. (Valera MC et al. Blood. 2012, in press). (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:S7 / S11
页数:5
相关论文
共 62 条
[1]  
Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0
[2]   Palmitoylation-dependent estrogen receptor α membrane localization:: Regulation by 17β-estradiol [J].
Acconcia, F ;
Ascenzi, P ;
Bocedi, A ;
Spisni, E ;
Tomasi, V ;
Trentalance, A ;
Visca, P ;
Marino, M .
MOLECULAR BIOLOGY OF THE CELL, 2005, 16 (01) :231-237
[3]   Prior hormone therapy and breast cancer risk in the Women's Health initiative randomized trial of estrogen plus progestin [J].
Anderson, Garnet L. ;
Chlebowski, Rowan T. ;
Rossouw, Jacques E. ;
Rodabough, Rebecca J. ;
McTiernan, Anne ;
Margolis, Karen L. ;
Aggerwal, Anita ;
Curb, J. David ;
Hendrix, Susan L. ;
Hubbell, F. Allan ;
Khandekar, Jamardan ;
Lane, Dorothy S. ;
Lasser, Norman ;
Lopez, Ana Maria ;
Potter, JoNell ;
Ritenbaugh, Cheryl .
MATURITAS, 2006, 55 (02) :103-115
[4]   Effects of conjugated, equine estrogen in postmenopausal women with hysterectomy - The women's health initiative randomized controlled trial [J].
Anderson, GL ;
Limacher, M ;
Assaf, AR ;
Bassford, T ;
Beresford, SAA ;
Black, H ;
Bonds, D ;
Brunner, R ;
Brzyski, R ;
Caan, B ;
Chlebowski, R ;
Curb, D ;
Gass, M ;
Hays, J ;
Heiss, G ;
Hendrix, S ;
Howard, BV ;
Hsia, J ;
Hubbell, A ;
Jackson, R ;
Johnson, KC ;
Judd, H ;
Kotchen, JM ;
Kuller, L ;
LaCroix, AZ ;
Lane, D ;
Langer, RD ;
Lasser, N ;
Lewis, CE ;
Manson, J ;
Margolis, K ;
Ockene, J ;
O'Sullivan, MJ ;
Phillips, L ;
Prentice, RL ;
Ritenbaugh, C ;
Robbins, J ;
Rossouw, JE ;
Sarto, G ;
Stefanick, ML ;
Van Horn, L ;
Wactawski-Wende, J ;
Wallace, R ;
Wassertheil-Smoller, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (14) :1701-1712
[5]   Sterility and absence of histopathological defects in nonreproductive organs of a mouse ERβ-null mutant [J].
Antal, Maria Cristina ;
Krust, Andree ;
Chambon, Pierre ;
Mark, Manuel .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (07) :2433-2438
[6]   Genetic and pharmacologic strategies to determine the function of estrogen receptor α and estrogen receptor β in the cardiovascular system [J].
Arias-Loza, Paula Anahi ;
Jazbutyte, Virginija ;
Pelzer, Theo .
GENDER MEDICINE, 2008, 5 :S34-S45
[7]   Estrogens in vascular biology and disease:: where do we stand today? [J].
Arnal, Jean-Francois ;
Scarabin, Pierre-Yves ;
Tremollieres, Florence ;
Laurell, Henrik ;
Gourdy, Pierre .
CURRENT OPINION IN LIPIDOLOGY, 2007, 18 (05) :554-560
[8]   Estrogen Receptors and Endothelium [J].
Arnal, Jean-Francois ;
Fontaine, Coralie ;
Billon-Gales, Audrey ;
Favre, Julie ;
Laurell, Henrik ;
Lenfant, Francoise ;
Gourdy, Pierre .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2010, 30 (08) :1506-1512
[9]  
Ascenzi Paolo, 2006, Molecular Aspects of Medicine, V27, P299, DOI 10.1016/j.mam.2006.07.001
[10]   Hormones and heart disease in women: The timing hypothesis [J].
Barrett-Connor, Elizabeth .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2007, 166 (05) :506-510